bosentan anhydrous has been researched along with Hyperparathyroidism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burgos, ME; Felsenfeld, AJ; Jara, A; Jara, X; Mezzano, S; Valdivieso, A; von Höveling, A | 1 |
| Fujimura, S; Iwashita, K; Kanesaka, Y; Naomi, S; Tokunaga, H; Tomita, K | 1 |
2 other study(ies) available for bosentan anhydrous and Hyperparathyroidism
| Article | Year |
|---|---|
Effect of endothelin receptor antagonist on parathyroid gland growth, PTH values and cell proliferation in azotemic rats.
Topics: Animals; Antihypertensive Agents; Bosentan; Cell Proliferation; Endothelin Receptor Antagonists; Hyperparathyroidism; Male; Parathyroid Glands; Parathyroid Hormone; Phosphorus, Dietary; Rats; Rats, Sprague-Dawley; Sulfonamides; Uremia | 2006 |
Endothelin receptor antagonist prevents parathyroid cell proliferation of low calcium diet-induced hyperparathyroidism in rats.
Topics: Animals; Bosentan; Calcium; Calcium, Dietary; Cell Division; Endothelin Receptor Antagonists; Endothelin-1; Hyperparathyroidism; Male; Parathyroid Glands; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2001 |